ATE418612T1 - Anthrax-impfstoff - Google Patents
Anthrax-impfstoffInfo
- Publication number
- ATE418612T1 ATE418612T1 AT99941953T AT99941953T ATE418612T1 AT E418612 T1 ATE418612 T1 AT E418612T1 AT 99941953 T AT99941953 T AT 99941953T AT 99941953 T AT99941953 T AT 99941953T AT E418612 T1 ATE418612 T1 AT E418612T1
- Authority
- AT
- Austria
- Prior art keywords
- anthrax vaccine
- aureus
- intoxication
- subjects
- inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9241698P | 1998-07-10 | 1998-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE418612T1 true ATE418612T1 (de) | 2009-01-15 |
Family
ID=22233100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99941953T ATE418612T1 (de) | 1998-07-10 | 1999-07-09 | Anthrax-impfstoff |
AT99943610T ATE443768T1 (de) | 1998-07-10 | 1999-07-09 | Impfstoff gegen staphylokokken-vergiftung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99943610T ATE443768T1 (de) | 1998-07-10 | 1999-07-09 | Impfstoff gegen staphylokokken-vergiftung |
Country Status (7)
Country | Link |
---|---|
US (2) | US6632640B1 (de) |
EP (2) | EP1097212B1 (de) |
AT (2) | ATE418612T1 (de) |
AU (2) | AU761021B2 (de) |
CA (2) | CA2337966A1 (de) |
DE (2) | DE69941454D1 (de) |
WO (2) | WO2000002522A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
DE69941454D1 (de) * | 1998-07-10 | 2009-11-05 | U S Medical Res Inst Of Infect | Impfstoff gegen staphylokokken-vergiftung |
JP2002522055A (ja) * | 1998-08-13 | 2002-07-23 | ウォルター リード アーミー インスティテュート オブ リサーチ | バクテリア性超抗原ワクチン |
WO2000062856A1 (en) | 1999-04-16 | 2000-10-26 | Johnson & Johnson Consumer Companies, Inc. | Drug delivery device comprising a dual chamber reservoir |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
GB0016702D0 (en) | 2000-07-08 | 2000-08-23 | Secr Defence Brit | Expression system |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
GB0118009D0 (en) * | 2001-07-24 | 2001-09-19 | Regma Biotechnologies Ltd | Novel preparation |
AU2002327614B2 (en) * | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
AU2002242935A1 (en) | 2001-12-05 | 2003-06-17 | Rakesh Bhatnagar | A process for the preparation of a non-toxic anthrax vaccine |
WO2003087378A1 (en) * | 2002-04-11 | 2003-10-23 | Powderject Research Limited | Nucleic acid immunization |
US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
EP1575505A4 (de) * | 2002-09-10 | 2007-01-24 | Vical Inc | Codon-optimierte vakzine auf polynucleotid-basis gegen infektionen mit bacillus anthracis |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
JP4991108B2 (ja) | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | 多抗原性アルファウイルス・レプリコン粒子及び方法 |
WO2004085660A2 (en) * | 2003-03-20 | 2004-10-07 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
WO2005034841A2 (en) * | 2003-05-14 | 2005-04-21 | Merck & Co., Inc. | Anthrax vaccine |
ES2327643T3 (es) * | 2003-07-11 | 2009-11-02 | Alphavax, Inc. | Vacunas contra citomegalovirus basadas en alfavirus. |
WO2005026203A2 (en) | 2003-09-18 | 2005-03-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna promoters and anthrax vaccines |
EP1735338B1 (de) | 2004-02-11 | 2013-04-24 | Ligocyte Pharmaceuticals, Inc. | Anthrax-antigene und anwendungsverfahren |
EP1791559A2 (de) | 2004-09-22 | 2007-06-06 | GlaxoSmithKline Biologicals SA | Immunogene zusammensetzung |
KR20080052509A (ko) * | 2005-04-11 | 2008-06-11 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 | 유행성 독감 바이러스에 대한 백신 |
CN101242856A (zh) | 2005-09-09 | 2008-08-13 | 莱博法姆公司 | 持续药物释放的组合物 |
CN103169960A (zh) | 2006-03-30 | 2013-06-26 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
US20070248960A1 (en) * | 2006-04-19 | 2007-10-25 | Rees Dianne M | Arrays containing cleavable RNAi molecules |
PL2183368T3 (pl) * | 2007-06-21 | 2016-12-30 | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych | |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
US8840906B2 (en) | 2007-08-31 | 2014-09-23 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung disease and conditions |
WO2009063507A1 (en) * | 2007-11-12 | 2009-05-22 | Rakesh Bhatnagar | Dna vaccine against anthrax |
WO2010014304A1 (en) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
US20110262477A1 (en) | 2008-10-06 | 2011-10-27 | University Of Chicago | Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins |
EP3002293A1 (de) | 2009-04-03 | 2016-04-06 | The University of Chicago | Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2555794A4 (de) | 2010-04-05 | 2014-01-15 | Univ Chicago | Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker |
ES2655701T3 (es) | 2010-07-02 | 2018-02-21 | The University Of Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SpA) |
US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
WO2012170097A2 (en) * | 2011-03-16 | 2012-12-13 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
AU2012296576B2 (en) | 2011-08-15 | 2017-09-07 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
JP6251730B2 (ja) | 2012-04-26 | 2017-12-20 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 黄色ブドウ球菌(staphylococcusaureus)疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 |
WO2013162746A1 (en) | 2012-04-26 | 2013-10-31 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
WO2014205111A1 (en) | 2013-06-19 | 2014-12-24 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
EA201891601A1 (ru) | 2016-01-10 | 2019-03-29 | Неоткс Терапьютикс Лтд. | Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей |
US11505722B2 (en) * | 2017-06-30 | 2022-11-22 | The Boeing Company | Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials |
US11260120B2 (en) | 2017-07-27 | 2022-03-01 | Integrated Biotherapeutic Vaccines, Inc. | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids |
EP3969043A1 (de) | 2019-05-15 | 2022-03-23 | Neotx Therapeutics Ltd. | Krebsbehandlung |
EP4038091A1 (de) | 2019-10-02 | 2022-08-10 | Janssen Vaccines & Prevention B.V. | Staphylococcus-peptide und verfahren zur verwendung |
CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2128415A1 (en) * | 1992-01-28 | 1993-08-05 | John W. Kappler | Protective effects of mutated superantigens |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
EP0716148B1 (de) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Rekombinanter Alphavirus Vektor |
US5641655A (en) * | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
GB9604045D0 (en) * | 1996-02-26 | 1996-04-24 | Smithkline Beecham Plc | Novel compounds |
GB9618107D0 (en) * | 1996-08-30 | 1996-10-09 | Secr Defence | Vaccine production |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
CA2320512A1 (en) * | 1998-02-15 | 1999-08-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Novel preventives/remedies for immunopathy |
EP1092031A2 (de) * | 1998-06-29 | 2001-04-18 | U.S. Medical Research Institute of Infectious Diseases | Marburg-virus impfstoffe |
DE69941454D1 (de) * | 1998-07-10 | 2009-11-05 | U S Medical Res Inst Of Infect | Impfstoff gegen staphylokokken-vergiftung |
JP2002522055A (ja) * | 1998-08-13 | 2002-07-23 | ウォルター リード アーミー インスティテュート オブ リサーチ | バクテリア性超抗原ワクチン |
AU771774B2 (en) * | 1998-12-07 | 2004-04-01 | U.S. Medical Research Institute Of Infectious Diseases | Live attenuated Venezuelan equine encephalitis vaccine |
-
1999
- 1999-07-09 DE DE69941454T patent/DE69941454D1/de not_active Expired - Fee Related
- 1999-07-09 US US09/350,755 patent/US6632640B1/en not_active Expired - Fee Related
- 1999-07-09 AT AT99941953T patent/ATE418612T1/de not_active IP Right Cessation
- 1999-07-09 AT AT99943610T patent/ATE443768T1/de not_active IP Right Cessation
- 1999-07-09 EP EP99941953A patent/EP1097212B1/de not_active Expired - Lifetime
- 1999-07-09 CA CA002337966A patent/CA2337966A1/en not_active Abandoned
- 1999-07-09 WO PCT/US1999/015568 patent/WO2000002522A2/en active IP Right Grant
- 1999-07-09 CA CA002339355A patent/CA2339355A1/en not_active Abandoned
- 1999-07-09 EP EP99943610A patent/EP1097213B1/de not_active Expired - Lifetime
- 1999-07-09 AU AU56673/99A patent/AU761021B2/en not_active Ceased
- 1999-07-09 AU AU55426/99A patent/AU758019B2/en not_active Ceased
- 1999-07-09 DE DE69940157T patent/DE69940157D1/de not_active Expired - Fee Related
- 1999-07-09 WO PCT/US1999/015569 patent/WO2000002523A2/en active IP Right Grant
-
2003
- 2003-04-02 US US10/405,871 patent/US7374931B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2339355A1 (en) | 2000-01-20 |
DE69941454D1 (de) | 2009-11-05 |
WO2000002522A3 (en) | 2000-10-12 |
AU758019B2 (en) | 2003-03-13 |
WO2000002522A9 (en) | 2001-04-05 |
US6632640B1 (en) | 2003-10-14 |
DE69940157D1 (en) | 2009-02-05 |
AU761021B2 (en) | 2003-05-29 |
EP1097213A2 (de) | 2001-05-09 |
WO2000002523A9 (en) | 2000-07-27 |
EP1097212A2 (de) | 2001-05-09 |
WO2000002522A2 (en) | 2000-01-20 |
US20040009183A1 (en) | 2004-01-15 |
CA2337966A1 (en) | 2000-01-20 |
US7374931B2 (en) | 2008-05-20 |
EP1097213B1 (de) | 2009-09-23 |
AU5542699A (en) | 2000-02-01 |
WO2000002523A3 (en) | 2000-11-23 |
ATE443768T1 (de) | 2009-10-15 |
EP1097212B1 (de) | 2008-12-24 |
AU5667399A (en) | 2000-02-01 |
WO2000002523A2 (en) | 2000-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE418612T1 (de) | Anthrax-impfstoff | |
TR200806259T2 (tr) | Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler | |
HK1080506A1 (en) | Fusion proteins of mycobacterium tuberculosis | |
EA200100565A1 (ru) | Новые стрептококковые антигены | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
BRPI0417823A (pt) | métodos para uso de bifidobactérias probióticas para animais de estimação | |
BR0208450B1 (pt) | acoplamento de velocidade constante e sistema de controle do mesmo. | |
WO2003070187A3 (en) | Fusion proteins of mycobacterium tuberculosis | |
CY1111119T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν κολλοειδες διοξειδιο του πυριτιου | |
BR0200294B1 (pt) | sistema e mÉtodo de processamento de algodço. | |
TR200000115T2 (tr) | Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler. | |
BR0310042A (pt) | Vacinas de combinação mucosal para meningite bacteriana | |
WO2005009378A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
WO2002034773A3 (en) | Streptococcal genes | |
HUP0301634A2 (hu) | Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera | |
DK1625393T3 (da) | Vacciner, som medfører beskyttelse mod infektion af Streptococcus pneumonia | |
WO2003053338A3 (en) | Novel chimeric rev, tat, and nef antigens | |
BR0115646A (pt) | Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente | |
DK0894500T3 (da) | Streptococcus equi-vaccine | |
DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
WO2003049670A3 (en) | Adjuvant formulations for bacterial and virus vaccines and method of making same | |
WO2004073604A3 (en) | Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity | |
AR039035A1 (es) | Proteinas con dominios tipo ig bacterianos (big) presentes en especies de leptospira | |
BRPI0414853A (pt) | copolìmeros de 1-vinilpirrolidin-2-ona/ésteres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |